Century Therapeutics, Inc.

NasdaqGS IPSC

Century Therapeutics, Inc. Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2024: 0.26

Century Therapeutics, Inc. Debt to Equity Ratio is 0.26 for the Trailing 12 Months (TTM) ending September 30, 2024, a 46.35% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.

Century Therapeutics, Inc. Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2023 was 0.18, a 93.27% change year over year.
Century Therapeutics, Inc. Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2022 was 0.09, a -35.41% change year over year.
Century Therapeutics, Inc. Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2021 was 0.14.

Key data

Date	Debt to Equity Ratio	Debt to Income Ratio	Debt to Tangible Net Worth Ratio	Dividend Coverage Ratio

NasdaqGS: IPSC

Century Therapeutics, Inc.

CEO	Mr. Brent Pfeiffenberger M.B.A., Pharm.D.
IPO Date	June 18, 2021
Location	United States
Headquarters	3675 Market Street
Employees	152
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.

Key trends

Past 5 years